Oncimmune Holdings plc (LON:ONC), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, today announced it has signed three new exclusive distribution agreements for its EarlyCDT®- Lung test with LabLab ApS, Diuvita Diagnostics AS and XboXLab AB in Denmark, Norway and Sweden respectively.
The agreements allow for the sale of the CE marked kit to local laboratories and as a central laboratory test. The three agreements are for an initial term of three years and include minimum sales commitments of approximately £500,000. First sales are expected to commence late in 2017/early 2018.
Geoffrey Hamilton-Fairley, CEO of Oncimmune Holdings plc, commented: “These distribution agreements, which we anticipate to be the first of many across Europe, give us full coverage of the Scandinavian region where we have received a great deal of interest in our EarlyCDT®-Lung test. As part of the strategy indicated at the time of our IPO, we outlined our plan to grow into multiple regions with multiple products and these latest agreements not only show our commitment to that strategy but also indicate the strength and potential of our EarlyCDT®-Lung test and kit.”
